Familial hypocalciuric hypercalcaemia (FHH) is a dominantly inherited, lifelong benign disorder characterised by asymptomatic hypercalcaemia, relative hypocalciuria and variable parathyroid hormone levels. It is caused by loss-of-function pathogenic variants in the calcium-sensing receptor (CASR) gene. Primary hyperparathyroidism (PHPT) is characterised by variable hypercalcaemia in the context of non-suppressed parathyroid hormone levels. Unlike patients with FHH, patients with severe hypercalcaemia due to PHPT are usually symptomatic and are at risk of end-organ damage affecting the kidneys, bone, heart, gastrointestinal system and CNS. Surgical resection of the offending parathyroid gland(s) is the treatment of choice for PHPT, while dietary adjustment and reassurance is the mainstay of management for patients with FHH. The occurrence of both FHH and primary hyperparathyroidism (PHPT) in the same patient has been described. We report an interesting case of FHH due to a novel CASR variant confirmed in a mother and her two daughters and the possible coexistence of FHH and PHPT in the mother, highlighting the challenges involved in diagnosis and management.
CITATION STYLE
Sagi, S. V., Joshi, H., Trotman, J., Elsey, T., Swamy, A., Rajkanna, J., … Park, S. M. (2020). A novel CASR variant in a family with familial hypocalciuric hypercalcaemia and primary hyperparathyroidism. Endocrinology, Diabetes and Metabolism Case Reports, 2020(1), 1–6. https://doi.org/10.1530/EDM-20-0084
Mendeley helps you to discover research relevant for your work.